Developer docs
API playgroundTry for free, no card

Search company profiles

aMoon Fund

Full company profile

uuid0002eih

Namestring
aMoon Fund
Legal namestring
aMoon Ventures Y.SH. Ltd
Websiteurl
amoon.fund
Company typeenum
Private
Founded yearint
2016
Descriptiontext

aMoon is a private Israeli venture capital firm specializing in healthcare and life sciences, operating from Ra'anana, Israel with a secondary office in Boston. It invests across the healthcare stack — biopharma, medtech, diagnostics, and digital health — through two flagship vehicles: aMoon Velocity (early-stage) and aMoon Growth (late-stage). The firm was co-founded by Yair Schindel, MD, MBA, and is led by a partnership of scientists, physicians and operators (Tomer Berkovitz, PhD; Todd Sone, MBA; Moshic Mor, MBA; Yaron Daniely, PhD, MBA, who also heads aMoon Alpha; plus Partners Reut Shema, PhD and Roy Wiesner, Adv., MPA, and Portfolio Manager Patrick Rivers).

Layered on top of the two funds is aMoon Alpha, an in-house value-creation platform organized into three programmatic workstreams — Talent (global talent engine sourcing entrepreneurs and operators), Bridges (network connecting portfolio companies to Wall Street co-investors, large Biopharma/MedTech/Tech corporates, payers/providers, and research institutions), and Intelligence (proprietary research and trend analysis). aMoon also co-founded the LEAP HealthTech accelerator with 8200Bio, Rabin Medical Center and AWS, a 14-week program that has produced a founder pipeline from the Israeli tech-clinical ecosystem.

The business model is traditional venture capital economics — management fees on committed/limited-partner capital and carried interest on exits — with portfolio monetization demonstrated via NASDAQ-listed names (Adicet/ACET, Akoya Biosciences/AKYA, Ayala Pharmaceuticals/ADXS) and recent active rounds (MAGENTIQ EYE Series A led in July 2025; Connie Health $40M Series B participation in June 2026). Fund terms, AUM and check sizes are not publicly disclosed.

Short descriptiontext

aMoon is an Israeli healthcare and life sciences venture capital firm operating two funds (aMoon Velocity for early-stage and aMoon Growth for late-stage) plus an in-house value-creation platform (aMoon Alpha), serving healthtech and biotech founders globally with capital, talent, and corporate bridging.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRa'anana, Israel
HQ citystring
Ra'anana
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, life sciences investing, healthtech startup funding, biopharma growth equity, venture capital funds
Industry3 codes
PRIMARYFSAEAGAJ
Industry-Specialist / Sector-Focused M&A Advisory
SECONDARYBPAHAOAE
Equity Capital Advisory (Private Equity Placements, Growth Capital)
SECONDARYBPAHADAC
M&A Advisory (Buy-side/Sell-side)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Open-End Investment Funds525910
SIC code2 codes
  • Security Brokers, Dealers & Flotation Companies6211
  • Investment Advice6282
Product category
Healthcare Venture Capital
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Fund Management & Investment Returns
TypeManaged Services
Description

aMoon operates two flagship funds — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — investing in Israeli and global healthcare/healthtech companies pursuing disruptive solutions for high unmet medical needs. As a fund manager (aMoon Ventures Y.SH. Ltd), revenue is generated via traditional VC economics: management fees on committed/limited-partner capital and carried interest on investment returns, with portfolio exits delivered through IPOs (e.g., NASDAQ: ACET, AKYA, ADXS) and M&A.

amoon.fund
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details1 tier
1aMoon Velocity — early-stage fund; aMoon Growth — late-stage fund
ModelOtherBilling cadenceMulti-year contract
Notes

Fund vehicle terms (ticket size, valuation, ownership targets) are not publicly disclosed; participation is by invitation to LPs and co-investors.

amoon.fund
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1aMoon Velocity
Description

Early-stage investment fund focusing on early-stage healthcare companies pursuing disruptive solutions for high unmet medical needs.

amoon.fund
+2 more records
Core offering1 text field

aMoon is a healthcare-focused venture capital firm that manages two flagship funds — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — investing in Israeli and global healthtech, biopharma, medtech, and digital health companies pursuing disruptive solutions for high unmet medical needs. The firm layers an in-house value-creation platform, aMoon Alpha (Talent, Bridges, Intelligence), on top of the funds to support portfolio company execution, and co-runs the LEAP HealthTech accelerator with 8200Bio, Rabin Medical Center, and AWS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Portfolio company Connie Health raised $40M Series B (aMoon as existing investor) bringing total funding to $85M; completed 10th acquisition (Clearlink's Medicare business)
+4 more records
Product overview1 text field

aMoon Fund is a healthcare-focused venture capital firm, not a software product company. Its offering is structured as a platform-plus-modules architecture comprising two core investment vehicles — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — that invest in healthcare companies pursuing disruptive solutions for high unmet medical needs. Layered on top of these funds is aMoon Alpha, an in-house value-creation platform with three programmatic modules (Talent, Bridges, Intelligence) that supports portfolio companies operationally. aMoon also co-founded the LEAP HealthTech Startup Accelerator together with 8200Bio, Rabin Medical Center, and AWS, which extends its offering into HealthTech venture formation.

Product and service4 records
1aMoon Velocity
CategoryEarly-stage investment fund
Description

Early-stage venture fund that invests in healthcare companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. Targets pre-seed, seed, and Series A Israeli healthtech entrepreneurs leveraging breakthroughs at the convergence of tech and biology.

2aMoon Growth
CategoryLate-stage investment fund
Description

Late-stage venture fund that invests in healthcare companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. Provides growth capital, IPO readiness, and M&A support for more mature Israeli and global healthcare/healthtech companies ready to scale, IPO, or pursue strategic transactions.

3aMoon Alpha
CategoryIn-house portfolio support platform
Description

In-house value-creation team dedicated to strengthening portfolio companies' execution capabilities and unlocking additional value. Comprises three programs: Talent (global talent engine for entrepreneurs and managerial candidates), Bridges (connects portfolio companies with Biopharma, MedTech and Tech corporates, payers, and research institutions), and Intelligence (proprietary research and intelligence sources to support investment theses and market insights).

4LEAP HealthTech Startup Accelerator
CategoryStartup accelerator program
Description

First-of-its-kind HealthTech accelerator co-created by aMoon with 8200Bio, Rabin Medical Center, and AWS. Brings together exceptional tech talent and practicing clinicians over a 14-week program of clinical tours, workshops, validation sessions, lectures, and panels to form the next wave of HealthTech startups in the Israeli ecosystem.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
18200Bio
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-runner (with aMoon, Rabin Medical Center and AWS) of the inaugural LEAP cohort launched end of 2022 — a 14-week program to bring together tech talent and practicing clinicians to form the next wave of HealthTech startups. aMoon helped bring this program to life and supports identification and transition of exceptional tech talent into healthcare.

amoon.fund
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-runner (with aMoon, 8200Bio and AWS) of the LEAP HealthTech program. Brings in clinical expertise from Beilinson's Innovation team and exposes founders to clinical realities through clinical tours, workshops and validation sessions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-partner (with aMoon, 8200Bio and Rabin Medical Center) of the LEAP HealthTech program; contributes market expertise and go-to-market know-how to help founders validate and scale ventures.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the world's largest healthcare-dedicated investment firms with multi-billion AUM across venture, growth, credit, and royalties. Directly comparable to aMoon as a specialist healthcare/life-sciences VC, though at significantly larger scale.

TypeDirect peer
Description

U.S.-based, science-driven healthcare and technology VC managing large early- and late-stage funds. Closely comparable to aMoon in its tech-bio convergence thesis, founder-led model, and willingness to back early-stage moonshot science.

TypeDirect peer
Description

Healthcare-focused investment firm with crossover, venture, and public-equity funds. Advisor Dr. Michael Sherman is a former RA Capital advisor, indicating direct relationship overlap. Comparable focus on biotech/healthtech investing across stages.

TypeDirect peer
Description

Healthcare-dedicated growth-equity firm that led Connie Health's $40M Series B alongside aMoon. Comparable as a healthcare specialist that co-invests at growth stage with Israeli/global healthtech companies.

TypeDirect peer
Description

Large U.S. venture firm with deep healthcare/biotech practice. Existing co-investor alongside aMoon in Connie Health, and explicitly named as a participating investor in the Series B. Comparable in willingness to back early-stage moonshot science at the convergence of tech and biology.

TypeDirect peer
Description

Israel's largest VC firm with a dedicated healthtech fund. Most direct geographic peer to aMoon within the Israeli healthtech ecosystem, competing for the same founder pool and co-invested in Connie Health.

TypeBroad incumbent
Description

Large multi-stage venture firm with a substantial healthcare practice (Bessemer Venture Partners, formerly the BVP healthcare team). Comparable in healthtech investing breadth but operates as a broad generalist rather than a healthtech specialist.

TypeDirect peer
Description

Biotech creation engine and investor behind Moderna. Comparable to aMoon in its tech-bio thesis, willingness to back moonshot science, and integrated value-creation platform; substantially larger AUM and a U.S. orientation.

TypeDirect peer
Description

Healthcare and tech investor founded by Bill Maris. Directly comparable in healthtech specialization, stage flexibility (seed to growth), and focus on tech-bio convergence — overlapping with aMoon's investment thesis.

TypeBroad incumbent
Description

Healthcare-focused investment firm with venture, growth, and public-market strategies, plus operating services for portfolio companies. Comparable integrated platform approach (similar to aMoon Alpha) and willingness to support founders across stages.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment72 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

aMoon Fund

Healthcare Venture Capitalamoon.fund

aMoon is an Israeli healthcare and life sciences venture capital firm operating two funds (aMoon Velocity for early-stage and aMoon Growth for late-stage) plus an in-house value-creation platform (aMoon Alpha), serving healthtech and biotech founders globally with capital, talent, and corporate bridging.

What aMoon Fund does

aMoon is a private Israeli venture capital firm specializing in healthcare and life sciences, operating from Ra'anana, Israel with a secondary office in Boston. It invests across the healthcare stack — biopharma, medtech, diagnostics, and digital health — through two flagship vehicles: aMoon Velocity (early-stage) and aMoon Growth (late-stage). The firm was co-founded by Yair Schindel, MD, MBA, and is led by a partnership of scientists, physicians and operators (Tomer Berkovitz, PhD; Todd Sone, MBA; Moshic Mor, MBA; Yaron Daniely, PhD, MBA, who also heads aMoon Alpha; plus Partners Reut Shema, PhD and Roy Wiesner, Adv., MPA, and Portfolio Manager Patrick Rivers).

Layered on top of the two funds is aMoon Alpha, an in-house value-creation platform organized into three programmatic workstreams — Talent (global talent engine sourcing entrepreneurs and operators), Bridges (network connecting portfolio companies to Wall Street co-investors, large Biopharma/MedTech/Tech corporates, payers/providers, and research institutions), and Intelligence (proprietary research and trend analysis). aMoon also co-founded the LEAP HealthTech accelerator with 8200Bio, Rabin Medical Center and AWS, a 14-week program that has produced a founder pipeline from the Israeli tech-clinical ecosystem.

The business model is traditional venture capital economics — management fees on committed/limited-partner capital and carried interest on exits — with portfolio monetization demonstrated via NASDAQ-listed names (Adicet/ACET, Akoya Biosciences/AKYA, Ayala Pharmaceuticals/ADXS) and recent active rounds (MAGENTIQ EYE Series A led in July 2025; Connie Health $40M Series B participation in June 2026). Fund terms, AUM and check sizes are not publicly disclosed.

aMoon Fund firmographics

Firmographics
Name
aMoon Fund
Legal name
aMoon Ventures Y.SH. Ltd
Website
https://amoon.fund
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
aMoon is an Israeli healthcare and life sciences venture capital firm operating two funds (aMoon Velocity for early-stage and aMoon Growth for late-stage) plus an in-house value-creation platform (aMoon Alpha), serving healthtech and biotech founders globally with capital, talent, and corporate bridging.
Ownership category
akta.pro rank

aMoon Fund industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Open-End Investment Funds (525910)
SIC
Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
akta.pro industry
PRIMARYFSAEAGAJ
Industry-Specialist / Sector-Focused M&A Advisory
SECONDARYBPAHAOAE
Equity Capital Advisory (Private Equity Placements, Growth Capital)
SECONDARYBPAHADAC
M&A Advisory (Buy-side/Sell-side)

Keywords

  • Healthcare venture capital
  • Life sciences investing
  • Healthtech startup funding
  • Biopharma growth equity
  • Venture capital funds

Where aMoon Fund is headquartered

Location

Headquarters

HQ city
Ra'anana
HQ country
Israel
HQ region
Middle East

Offices2 records

Markets served

aMoon Fund business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Venture Capital Fund Management & Investment Returns: aMoon operates two flagship funds — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — investing in Israeli and global healthcare/healthtech companies pursuing disruptive solutions for high unmet medical needs. As a fund manager (aMoon Ventures Y.SH. Ltd), revenue is generated via traditional VC economics: management fees on committed/limited-partner capital and carried interest on investment returns, with portfolio exits delivered through IPOs (e.g., NASDAQ: ACET, AKYA, ADXS) and M&A.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractaMoon Velocity — early-stage fund; aMoon Growth — late-stage fund

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

aMoon Fund product offering

Product offering

Core offering

aMoon is a healthcare-focused venture capital firm that manages two flagship funds — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — investing in Israeli and global healthtech, biopharma, medtech, and digital health companies pursuing disruptive solutions for high unmet medical needs. The firm layers an in-house value-creation platform, aMoon Alpha (Talent, Bridges, Intelligence), on top of the funds to support portfolio company execution, and co-runs the LEAP HealthTech accelerator with 8200Bio, Rabin Medical Center, and AWS.

Product overview

aMoon Fund is a healthcare-focused venture capital firm, not a software product company. Its offering is structured as a platform-plus-modules architecture comprising two core investment vehicles — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — that invest in healthcare companies pursuing disruptive solutions for high unmet medical needs. Layered on top of these funds is aMoon Alpha, an in-house value-creation platform with three programmatic modules (Talent, Bridges, Intelligence) that supports portfolio companies operationally. aMoon also co-founded the LEAP HealthTech Startup Accelerator together with 8200Bio, Rabin Medical Center, and AWS, which extends its offering into HealthTech venture formation.

Differentiator

Problem solved

Functional benefit

Brands

  • aMoon Velocity: Early-stage investment fund focusing on early-stage healthcare companies pursuing disruptive solutions for high unmet medical needs.
  • aMoon Growth
  • aMoon Alpha

Products and services

  • aMoon Velocity Early-stage venture fund that invests in healthcare companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. Targets pre-seed, seed, and Series A Israeli healthtech entrepreneurs leveraging breakthroughs at the convergence of tech and biology.
  • aMoon Growth Late-stage venture fund that invests in healthcare companies pursuing disruptive, cutting-edge solutions for high unmet medical needs. Provides growth capital, IPO readiness, and M&A support for more mature Israeli and global healthcare/healthtech companies ready to scale, IPO, or pursue strategic transactions.
  • aMoon Alpha In-house value-creation team dedicated to strengthening portfolio companies' execution capabilities and unlocking additional value. Comprises three programs: Talent (global talent engine for entrepreneurs and managerial candidates), Bridges (connects portfolio companies with Biopharma, MedTech and Tech corporates, payers, and research institutions), and Intelligence (proprietary research and intelligence sources to support investment theses and market insights).
  • LEAP HealthTech Startup Accelerator First-of-its-kind HealthTech accelerator co-created by aMoon with 8200Bio, Rabin Medical Center, and AWS. Brings together exceptional tech talent and practicing clinicians over a 14-week program of clinical tours, workshops, validation sessions, lectures, and panels to form the next wave of HealthTech startups in the Israeli ecosystem.

Quantifiable outcome

  • Portfolio company Connie Health raised $40M Series B (aMoon as existing investor) bringing total funding to $85M; completed 10th acquisition (Clearlink's Medicare business)
  • +4 more outcomes

Companies that use aMoon Fund

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles4 records

aMoon Fund technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

aMoon Fund partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • 8200BiocoreStrategic or Co-development PartnerCo-runner (with aMoon, Rabin Medical Center and AWS) of the inaugural LEAP cohort launched end of 2022 — a 14-week program to bring together tech talent and practicing clinicians to form the next wave of HealthTech startups. aMoon helped bring this program to life and supports identification and transition of exceptional tech talent into healthcare.
  • Rabin Medical Center (Beilinson)coreStrategic or Co-development PartnerCo-runner (with aMoon, 8200Bio and AWS) of the LEAP HealthTech program. Brings in clinical expertise from Beilinson's Innovation team and exposes founders to clinical realities through clinical tours, workshops and validation sessions.
  • Amazon Web Services (AWS)coreStrategic or Co-development PartnerCo-partner (with aMoon, 8200Bio and Rabin Medical Center) of the LEAP HealthTech program; contributes market expertise and go-to-market know-how to help founders validate and scale ventures.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

aMoon Fund competitors and assessment

Company assessment

Direct peers

  • OrbiMed: One of the world's largest healthcare-dedicated investment firms with multi-billion AUM across venture, growth, credit, and royalties. Directly comparable to aMoon as a specialist healthcare/life-sciences VC, though at significantly larger scale.
  • ARCH Venture Partners: U.S.-based, science-driven healthcare and technology VC managing large early- and late-stage funds. Closely comparable to aMoon in its tech-bio convergence thesis, founder-led model, and willingness to back early-stage moonshot science.
  • RA Capital Management: Healthcare-focused investment firm with crossover, venture, and public-equity funds. Advisor Dr. Michael Sherman is a former RA Capital advisor, indicating direct relationship overlap. Comparable focus on biotech/healthtech investing across stages.
  • HealthQuest Capital: Healthcare-dedicated growth-equity firm that led Connie Health's $40M Series B alongside aMoon. Comparable as a healthcare specialist that co-invests at growth stage with Israeli/global healthtech companies.
  • Khosla Ventures: Large U.S. venture firm with deep healthcare/biotech practice. Existing co-investor alongside aMoon in Connie Health, and explicitly named as a participating investor in the Series B. Comparable in willingness to back early-stage moonshot science at the convergence of tech and biology.
  • Pitango HealthTech: Israel's largest VC firm with a dedicated healthtech fund. Most direct geographic peer to aMoon within the Israeli healthtech ecosystem, competing for the same founder pool and co-invested in Connie Health.
  • Flagship Pioneering: Biotech creation engine and investor behind Moderna. Comparable to aMoon in its tech-bio thesis, willingness to back moonshot science, and integrated value-creation platform; substantially larger AUM and a U.S. orientation.
  • Section 32: Healthcare and tech investor founded by Bill Maris. Directly comparable in healthtech specialization, stage flexibility (seed to growth), and focus on tech-bio convergence — overlapping with aMoon's investment thesis.

Broad incumbents

  • Bessemer Venture Partners (BVP): Large multi-stage venture firm with a substantial healthcare practice (Bessemer Venture Partners, formerly the BVP healthcare team). Comparable in healthtech investing breadth but operates as a broad generalist rather than a healthtech specialist.
  • Deerfield Management: Healthcare-focused investment firm with venture, growth, and public-market strategies, plus operating services for portfolio companies. Comparable integrated platform approach (similar to aMoon Alpha) and willingness to support founders across stages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

aMoon Fund social profiles

Digital presence

aMoon Fund compliance and trust

Trust signal

Compliance1 record

aMoon Fund financial estimates

Financial estimate

Revenue estimate

Valuation estimate

aMoon Fund leadership team

Management profile

Number of profiles

Profiles17 records

aMoon Fund funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

aMoon Fund M&A and investment

M&A and investment

M&A

Investments72 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about aMoon Fund

What does aMoon Fund do?

aMoon is a healthcare-focused venture capital firm that manages two flagship funds — aMoon Velocity (early-stage) and aMoon Growth (late-stage) — investing in Israeli and global healthtech, biopharma, medtech, and digital health companies pursuing disruptive solutions for high unmet medical needs. The firm layers an in-house value-creation platform, aMoon Alpha (Talent, Bridges, Intelligence), on top of the funds to support portfolio company execution, and co-runs the LEAP HealthTech accelerator with 8200Bio, Rabin Medical Center, and AWS.

Is aMoon Fund a public or private company?

aMoon Fund is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was aMoon Fund founded?

aMoon Fund was founded in 2016. It employs 51 to 100 people.

Where is aMoon Fund based?

aMoon Fund is headquartered in Ra'anana, Israel, in the Middle East region.

How does aMoon Fund make money?

One revenue line is on record: venture Capital Fund Management & Investment Returns.

Who are aMoon Fund's main competitors?

Direct peers on record are OrbiMed, ARCH Venture Partners, RA Capital Management, HealthQuest Capital, Khosla Ventures, Pitango HealthTech, Flagship Pioneering and Section 32. Broad incumbents are Bessemer Venture Partners (BVP) and Deerfield Management.

Does aMoon Fund have an API?

No public API is recorded for aMoon Fund.

What industry is aMoon Fund in?

aMoon Fund's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSAEAGAJ, Industry-Specialist / Sector-Focused M&A Advisory, with a secondary code of BPAHAOAE, Equity Capital Advisory (Private Equity Placements, Growth Capital). Its NAICS code is 523940 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Venture Capital Access OnlineTech-Enabled Rural Health Care Leader Hopscotch Primary Care Announces $53 Million in Latest Funding RoundHopscotch Primary Care raised $53 million in Series D funding, led by 8VC and Town Hall Ventures. The company serves over 15,000 patients in rural Southeastern U.S. communities and will use the funds to expand into new markets and scale its technology-powered operations.PR NewswireLargest, Longest Real-World Study of Migraine in U.S. Veterans Finds that Nerivio® Helps Patients Successfully Skip Prescribed Migraine Medications in 3-out-of-4 of Their Migraine AttacksTheranica announced results from a peer-reviewed study of 466 U.S. veterans using Nerivio, a REN wearable, between November 2020 and February 2026. In 77% of treatments, veterans avoided prescribed migraine medication, with 61% using REN alone. The study was published in Military Medicine.BioSpaceConnie Health Announces Acquisition of Clearlink Insurance Agency and Series B Funding to Accelerate Growth in MedicareConnie Health completed its acquisition of Clearlink's Medicare business, its 10th acquisition, and announced a $40 million Series B led by HealthQuest Capital. The round brings total funding to $85 million, supporting further acquisitions and agent network growth.CoveragerConnie Health buys Clearlink’s Medicare businessConnie Health completed its acquisition of Clearlink's Medicare business and closed a $40 million Series B round led by HealthQuest Capital. The funding brings total investment to $85 million, and Clearlink is the tenth acquisition. Connie Health is positioning itself as a partner to Accountable Care Organizations and health systems.FierceBiotechFrench antibody biotech draws in $122M for end-of-year clinical pushFrench antibody biotech Adcytherix has closed a 105 million euro ($122 million) series A round led by Bpifrance, with participation from Kurma Partners, Andera Partners, Angelini Ventures, Citadel's Surveyor Capital, aMoon, and existing investors. The funding will support filing an investigational new drug application in the U.S. and clinical trial applications in the U.K., Canada and Europe by year-end for lead candidate ADCX-020, an antibody drug conjugate targeting cancers of high unmet need. The round represents the largest ADC-focused series A in Europe in 2025 and more than triples the company's 30 million euro seed funding from June 2024.Healthcare IT TodayMAGENTIQ EYE Secures Series A Investment Led by aMoon to Drive the Future of AI-Powered GastroenterologyMAGENTIQ EYE LTD. completed its Series A funding round led by aMoon to support the commercialization of its AI-powered gastroenterology software in the USA and Europe. The investment, which also included participation from Norgine Ventures BV, Nina Capital, Namarel Ventures SL, Nova Capital, and private investors, will fund continued development of MAGENTIQ-COLO and expansion into new diagnostic areas. Roy Wiesner joined the board as part of the deal to provide strategic guidance for global market access.BioSpaceIantrek Raises $42 Million Series C to Launch AlloFlo™ Uveo, a Breakthrough Interventional Glaucoma TherapyIantrek closed a $42 million Series C to fund the U.S. launch of AlloFlo Uveo, a surgical solution for the uveoscleral pathway. The company cites a 2025 study showing a mean IOP reduction of 34% and medication use cut by over 60%. First-in-human trials for its next product are completed, with a 2026 launch expected.PaMAGENTIQ EYE Secures Series A Investment Led by aMoon to Drive the Future of AI-Powered GastroenterologyMAGENTIQ EYE completed a Series A funding round led by aMoon, with participation from Norgine Ventures, Nina Capital, and others. The funds will support commercialization in the USA and Europe and development of its FDA- and CE-approved MAGENTIQ-COLO software for colonoscopy polyp detection. The company is also in clinical trials for GI diagnostic tools.PR NewswireMAGENTIQ EYE Secures Series A Investment Led by aMoon to Drive the Future of AI-Powered GastroenterologyMAGENTIQ EYE completed a Series A funding round led by aMoon, with participation from Norgine Ventures, Nina Capital, and others. The funds will support commercialization in the USA and Europe and development of its FDA- and CE-approved MAGENTIQ-COLO software for colonoscopy polyp detection. The company is also in clinical trials for GI diagnostic tools.PR NewswireMAGENTIQ EYE sichert sich ein Serie-A-Investment unter Führung von aMoon, um die Zukunft der KI-gestützten Gastroenterologie voranzutreibenMAGENTIQ EYE LTD, an AI-powered gastroenterology decision-support software company based in Haifa, Israel, announced the successful completion of its Series A funding round led by aMoon, Israel's largest HealthTech-focused investment fund. The round also included participation from Norgine Ventures BV, Nina Capital, Namarel Ventures SL, Nova Capital, and private investors Sake Bosch and Roon Doornink, with aMoon partner Roy Wiesner joining the company's board. The funding will support commercialization of its FDA and CE-approved MAGENTIQ-COLO colonoscopy software in the US and European markets, as well as further development of AI diagnostic tools for gastrointestinal conditions.